

Distribution of IP Weights




Figure S1. Distribution of inverse probability weighting in retained patients

Table S1. Demographic data of patients with multiple sclerosis in final cohort, total excluded, and lost to follow-up patients

Variable		Final cohort (n = 798)	Total excluded patients (n = 181)	Lost to follow-up (n = 72)	
Female/Male [n (%)]		624 (78.2)	150 (82.9)	59 (81.9%)	
Age (mean $\pm$ SD)		37.01 $\pm$ 9.17	36.53 $\pm$ 8.19	35.11 $\pm$ 8.01	
MS subtype [n (%)]	PP	45 (5.6)	3/157 (1.9)	2 (2.8%)	
	RR	590 (73.9)	113/157 (72.0)	52 (72.2%)	
	SP	163 (20.4)	41/157 (26.1)	18 (25.0 %)	
Duration of the disease (mean $\pm$ SD)		19.51 $\pm$ 13.47	21.52 $\pm$ 9.76	22.64 $\pm$ 10.12	
EDSS scores (mean $\pm$ SD)		4.04 $\pm$ 2.36	3.28 $\pm$ 2.59*	3.61 $\pm$ 2.76	
Underlying disorders [n (%)]	Arthritis	12 (1.5)	2/146 (1.4)	1 (1.4)	
	Autoimmune disorders	10 (1.3)	3/146 (2.1)	1 (1.4)	
	Diabetes	7 (0.9)	1/146 (0.7)	0 (0)	
	Hypertension	21 (2.6)	5/146 (3.4)	2 (2.8)	
	Hyperthyroidism	12 (1.5)	2/146 (1.4)	0 (0)	
	Hypothyroidism	63 (7.9)	22/146 (15.1)	8 (11.1)	
	Ischemic heart disease	6 (0.8)	2/146 (1.4)	0 (0)	
Class	Medication	Final cohort		Lost to follow-up	
		N	Time (month) (mean $\pm$ SD)	N	Time (month) (mean $\pm$ SD)
Moderate-efficacy DMTs	Dimethyl Fumarate	60	0.76 $\pm$ 3.05	4	1.36 $\pm$ 7.11
	Glatiramer acetate	179	2.47 $\pm$ 5.37	20	5.49 $\pm$ 14.89
	Interferon beta1-a	473	29.02 $\pm$ 41.27	46	33.92 $\pm$ 40.23
	Interferon beta1-b	153	9.49 $\pm$ 26.56	15	11.82 $\pm$ 31.34
High-efficacy DMTs	Fingolimod	189	2.52 $\pm$ 5.54	23	6.56 $\pm$ 13.61
	Natalizumab	172	2.69 $\pm$ 5.87	21	4.48 $\pm$ 9.26
	Ocrelizumab	45	0.33 $\pm$ 1.52	0*	NA
	Rituximab	394	5.46 $\pm$ 7.20	49*	7.33 $\pm$ 10.64
Off-label DMTs	Azathioprine	41	0.44 $\pm$ 2.12	1	0.42 $\pm$ 3.53

*Indicates $P < 0.05$ in comparison to retained (final cohort) patients

EDSS: Expanded disability status scale; NA: Not applicable; PP: Primary progressive; RR: Relapsing-remitting; SP: Secondary progressive